Year-end Report 1 January – 31 December 2022
· 72% growth in customer base and 43% growth in gross order intake · 510(k) clearance received for Episealer® Patellofemoral System, and timetable communicated for 510(k) application for Episealer MTP-System · Strengthening of commercial organization and preparation for US launch ongoing ”Today we are reporting on yet another quarter with clear steps in the right direction. The key metric of the number of surgeons using the Episealer grew by 72% in the quarter, and gross order intake was up by 43%. We clearly experienced positive developments in our commercial activities during the